Yield10 Bioscience, INC 8-K filings

Yield10 Bioscience and its subsidiaries have filed for Chapter 11 bankruptcy and intend to sell substantially all of their assets.

Yield10 Bioscience's proposed asset sale to Nuseed and subsequent dissolution were not approved by shareholders at the adjourned special meeting.

Yield10 Bioscience's special meeting to approve the sale of assets to Nuseed and company dissolution was adjourned due to a lack of sufficient shareholder votes, with a reconvened meeting scheduled for November 21, 2024.

Yield10 Bioscience reports the resignation of Dr. Kristi D. Snell as Vice President Research and Chief Science Officer, effective October 29, 2024.

Yield10 Bioscience has entered into an agreement to sell substantially all of its assets to Nuseed Nutritional US Inc. for up to $5 million, and plans to liquidate the company following the sale.

Yield10 Bioscience has obtained a secured promissory note of up to $3 million from Nuseed Nutritional US Inc., with an initial draw of $500,000, while continuing negotiations for a potential asset sale to Nuseed.

Yield10 Bioscience has terminated a $1 million convertible note with MPC Investment for a one-time payment of $500,000, resolving the outstanding debt.

Yield10 Bioscience has granted Nufarm a commercial license for its Omega-3 technology and is in negotiations for a potential sale of its remaining assets.

Yield10 Bioscience has officially increased its authorized common stock shares from 60 million to 150 million, effective June 12, 2024.

Yield10 Bioscience's stockholders approved an amendment to the 2018 Stock Option and Incentive Plan, increasing the number of shares available for issuance, and also approved an increase in the number of authorized shares of common stock.

Yield10 Bioscience announced its first quarter 2024 financial results, highlighting a $1 million milestone payment and a strategic focus on commercializing Camelina products for aquafeed and nutritional markets.

Yield10 Bioscience will be delisted from the Nasdaq Capital Market due to not meeting minimum stockholders' equity requirements, and its shares will begin trading on the OTC Markets Group platform.

Yield10 Bioscience has implemented a 1-for-24 reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

Yield10 Bioscience stockholders approved a reverse stock split at a ratio of 1-for-24 and the potential adjournment of a special meeting to solicit additional proxies.

Yield10 Bioscience announced its 2023 financial results, highlighting progress in Camelina commercialization, including a global license for biofuels and regulatory advancements for omega-3 traits.

Yield10 Bioscience is facing potential delisting from the Nasdaq Capital Market after failing to meet the minimum stockholder equity requirement, despite a previous extension to regain compliance with the minimum bid price rule.

Yield10 Bioscience has entered into agreements with institutional investors to exercise existing warrants, resulting in approximately $2.1 million in proceeds and the issuance of new warrants.

Yield10 Bioscience has entered into agreements with institutional investors to exercise existing warrants for $1.37 million, while also issuing new warrants.

Yield10 Bioscience has appointed Berkowitz Pollack Brant Advisors +CPAs, LLP as their new independent registered public accounting firm, effective immediately.

Yield10 Bioscience has received an extension to maintain its Nasdaq listing until May 13, 2024, contingent on meeting certain financial and reporting requirements.

Yield10 Bioscience has granted Vision Bioenergy Oilseeds an exclusive global license for its herbicide-tolerant Camelina technology for biofuel production, with a potential $3 million in payments to Yield10.

Yield10 Bioscience is prioritizing its Omega-3 Camelina program for commercialization in 2024 and is awaiting a decision regarding its Nasdaq listing.

Yield10 Bioscience has announced that RSM US LLP will not stand for reappointment as their independent auditor, prompting a search for a successor.